Please login to the form below

Not currently logged in
Email:
Password:

UK launch for gastrointestinal pharma firm

Belgian gastrointestinal pharmaceutical company Movetis has expanded its organisation with the launch of a new UK affiliate

Belgian gastrointestinal (GI) pharmaceutical company Movetis has expanded its organisation with the launch of a new UK affiliate.

Movetis (UK) will focus on the production of novel drugs to be used in the treatment of GI-related diseases where current options are limited.

The UK team includes eight representatives experienced in GI disorders. They will work with a range of products including Resolor (prucalopride), a treatment for chronic constipation in women in whom laxatives fail to provide adequate relief. Resolor was launched in the UK in March, 2010.

The company has said it plans further research involving prucalopride beyond its current indication.

Two products are currently in phase II development for Movetis, with a further two prioritised compounds in preclinical development. All products are aimed at addressing unmet needs in GI treatment.

David Trevor, general manager of Movetis (UK) said "The expansion of the business into the UK is an exciting time for Movetis. As a specialist GI pharmaceutical company we are able to focus our efforts and concentrate on ensuring new treatment options are made available for the management of gastrointestinal disease."

28th July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics